R&D Biopharma’s future in Ireland: Stability, regulation & talen... As increasing global competition from incentives is felt globally, Ireland needs to become even more agile.
Market Access Innovation beyond invention will bring novel medicines to Eu... Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.
R&D On the ICH E20 draft guideline (2025) for adaptive clinical ... A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.
News Eisai, Biogen face delay to subcutaneous Leqembi Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.
News FDA's ODAC delivers one loss, one win for AstraZeneca The FDA's cancer drugs committee backs AstraZeneca's Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.
News Amgen, AZ will pilot FDA's real-time clinical trial plan The FDA has published a plan to allow data from clinical trials to be reported to the agency as they occur in real time.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
